Ischemia-reperfusion (I/R) injury attenuates endotheliumdependent dilation of large coronary arteries both in vitro (1, 2) and in vivo (3, 4) . Endothelial dysfunction causes adverse outcome in the coronary circulation (5) . Reperfusion injury is caused by direct myocardial injury through coronary vasospasm, free radicals, and inflammatory responses (6, 7) . Furthermore, local coronary vasoconstrictions in response to vasoconstrictors (e.g., serotonin) are enhanced (8, 9) . However, the mechanism of I/R-induced vascular injury remains to be clarified.
Recent studies have demonstrated that Rho-kinase, an effector of the small guanosine triphosphatase Rho, is substantially involved in the pathogenesis of cardiovascular diseases (10) . Shimokawa et al. (10, 11) have recently found that hydroxyfasudil is a potent and specific inhibitor of Rho-kinase and markedly inhibits coronary hyperconstriction and macrophage migration. They also demonstrated that intracoronary serotonin induces coronary hypercontractions at the inflammatory coronary lesions both in vitro and in vivo, in which up-regulated Rho-kinase is substantially involved (12) . Recent studies demonstrated that endothelial expression and activity of Rho-kinase are enhanced by hypoxia, with a resultant down-regulation of endothelial nitric oxide synthase (eNOS) expression and reduced nitric oxide (NO) production (13) , and that Rho-kinase is also involved in a canine model of cerebral infarction associated with superoxide production and neutrophil infiltration (14) .
It is conceivable that Rho-kinase is involved in the mechanisms of I/R injury associated with reduced endothelial NO production. In this study, we thus examined whether hydroxyfasudil exerts protective effect on coronary I/R injury in vivo and, if so, whether NO is involved.
METHODS
Animal preparation. This study conformed to the Guideline on Animal Experiments of Kawasaki Medical School and the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health.
Mongrel dogs (15 to 25 kg, n ϭ 31) of either gender were anesthetized with morphine (3 mg/kg, intramuscular) and sodium pentobarbital (25 mg/kg, intravenous). After intubation, each animal was ventilated with a high-frequency jet ventilator (model VS600, IDC, Pittsburgh, Pennsylvania) with room air supplemented by 100% oxygen. Aortic pressure and left ventricular pressure were continuously monitored with an 8-F pigtail double manometer catheter (SPC-784A, Millar, Texas). The proximal portion of the left anterior descending coronary artery (LAD) was isolated and a transonic flow probe (T206, Transonic Systems, Ithaca, New York) was placed around the vessel. Needle-probe intravital microscope. The needle-probe (4.5 mm in diameter, VMS 1210, Nihon Kohden, Tokyo, Japan) contains a gradient index lens (with a magnification of 200) surrounded by light guide fibers and a double lumen sheath. A doughnut-shaped balloon on the tip avoids direct compression of the vessels by the needle tip (15) . Measurements of coronary diameters. We placed the needle probe gently on subepicardial microvessels. When a clear vascular image was obtained, end-diastolic vascular images were taken with 30 pictures/s (15) . Measurements of regional myocardial blood flow. Regional myocardial blood flow was determined by the nonradioactive microsphere (Sekisui Plastic Co, Ltd, Tokyo, Japan) technique, as previously described in detail (16) . Briefly, 1 ml of the microspheres suspension (2 to 4 ϫ 10 6 spheres) was injected into the left atrium 85 min after the onset of coronary occlusion. Just before microsphere administration, a reference blood flow sample was drawn from the femoral artery at a constant rate of 8 ml/min for 2 min. The X-ray fluorescence of the stable heavy elements was measured by a wavelength-dispersive spectrometer (model PW 1480, Phillips Co., Ltd., Eindhoven, the Netherlands) (16) . Myocardial blood flow was calculated according to the formula: time flow ϭ tissue counts ϫ (reference flow/ reference counts) and was expressed in ml/g per minute (16) . Western blotting. Proteins were separated on sodium dodecyl sulfate (SDS)/polyacrylamide gel electrophoresis as previously described (17) . The tissues were homogenized in a sample buffer (100 mM Tris-HCl [pH 6.8], 4% SDS, 0.2% glycerol). The tissue lysate was centrifuged and the supernatant collected. Protein concentration was quantified by a bicinchoninate (BCA) protein assay kit (Pierce Chemical, Rockford, Illinois). An aliquot of 10 g of protein from each sample was electrophoresed on a 7.5% SDSpolyacrylamide gel. Proteins were subsequently transferred to polyvinylidine difluoride membrane (Immobilon-P membrane, Millipore, Bedford, Massachusetts) electrophoretically (100 V for 1 h) and membranes were incubated with antibody. The antibodies used in this study were rabbit anti-phosphorylated ezrin/radixin/moesin (ERM) family, total ERM. The antibody against phosphorylated ERM recognizes human moesin (phosphorylated at Thr558), which also binds to the phosphorylated ezrin (Thr567) and radixin (Thr564). Therefore, we used the extent of phosphorylation of ERM as a marker of Rho-kinase activity. The levels of Western blot for phosphorylated ERM were normalized to those for total ERM as a control. Membranes were then incubated with a horseradish peroxidaseconjugated horse anti-rabbit immunoglobulin G antibody (1:5,000). Immunoreactivity was detected by enhanced chemiluminescence autoradiography (ECL Western blotting detection kit; Amersham Pharmacia Biotechnology, United Kingdom).
The obtained samples were washed with ice-cold TrisHCl buffer (pH 7.4), mixed with the sample buffer (4% sodium lauryl sulfate, 12% beta-mercaptoethanol, and 20% glycerol in 100 mM Tris-HCl [pH 6.8]), sonicated (1 min), boiled (3 min), and finally centrifuged (10,000 g, 60 min, 4°C). The resultant supernatant was stored at Ϫ80°C until use. The separation of proteins was carried out according to the previous study (18) , with a minor modification. The relative intensity of immunoreactive bands was quantified by Image Master 1D Elite software (Amersham Biotech, Buckinghamshire, United Kingdom), and the data were estimated as percentage of each control. Experimental protocols. After the surgical procedure and instrumentation, at least 30 min were allowed for stabilization while hemodynamic variables were monitored. The following protocols were examined.
1. We infused graded doses of hydroxyfasudil (10, 30, and 100 g/kg, IC), and coronary vascular responses were 
RESULTS
Coronary vasodilator effects of hydroxyfasudil. Intracoronary administration of hydroxyfasudil caused a significant coronary vasodilation of both small arteries and arterioles (Figs. 2a and 2b, both p Ͻ 0.05, 10 g/kg vs. 30 and 100 g/kg) in a dose-dependent manner under control conditions with a resultant increase in CBF (Fig. 2c , p Ͻ 0.05, C vs. 10, 30 and 100 g/kg). Intracoronary hydroxyfasudil did not significantly alter mean aortic pressure or heart rate ( Table 1) . Hemodynamics and blood gases during I/R injury. In each experimental condition, mean aortic pressure and heart rate at baseline were constant and comparable ( 
variables at baseline did not significantly change after I/R compared with those before I/R ( Table 1) . (Figs. 6a and 6b) . Similarly, the increase in CBF to papaverine (Fig. 6c) was also comparable under all conditions in both-sized arteries. Those coronary vasodilator responses were resistant to the blockade of NO synthesis with L-NMMA (Figs. 6a and 6b) . Activation of Rho-kinase by ischemia-reperfusion causes down-regulation of eNOS protein expression. Rhokinase activity after a 90-min period of ischemia was significantly greater in the ischemic LAD than in the nonischemic LCX in the control group (Fig. 7a , p Ͻ 0.01). This Rho-kinase activation was significantly suppressed by hydroxyfasudil in the ischemic LAD (Fig. 7a , p Ͻ 0.01). Expression of eNOS protein in the ischemic endocardium of the LAD area (as determined by Western blotting) was significantly decreased (79 Ϯ 4%, p Ͻ 0.05) compared with the nonischemic endocardium of the LCX area (100 Ϯ 7%), which was also improved by hydroxyfasudil (105 Ϯ 6%) (Fig. 7b , p Ͻ 0.05). There was no significant difference in the eNOS expression in the epicardium between the LAD and LCX area (Fig. 7c) . Effect of Rho-kinase inhibition on I/R-induced myocardial infarct size. Ischemia-reperfusion injury caused myocardial infarct area that was approximately 50% of the left ventricular risk area, and intracoronary L-NMMA did not further increase the I/R-induced infarction size (Fig. 8a ). Intracoronary pretreatment with hydroxyfasudil markedly reduced the infarct size (p Ͻ 0.01 vs. control), and this beneficial effect of hydroxyfasudil was significantly attenuated by L-NMMA (Fig. 8a p Ͻ 0.01) . In the control group, there was an inverse relation between the infarct area and collateral blood flow measured by microsphere technique (r ϭ 0.93, p Ͻ 0.01), and hydroxyfasudil significantly shifted the regression line downward as compared with the control group (p Ͻ 0.01), that is, smaller infarct size for a given collateral flow (Fig. 8b) .
Effects of Rho

DISCUSSION
The major findings of the present in vivo study in the canine coronary microcirculation were that: 1) a specific Rhokinase inhibitor hydroxyfasudil preserved the endotheliumdependent coronary vasodilator responses after coronary I/R injury, 2) hydroxyfasudil also reduced myocardial infarct size, and 3) NO may be involved in those cardiovascular protective effects of hydroxyfasudil. To the best of our knowledge, this is the first report that demonstrates the usefulness of a Rho-kinase inhibitor to prevent coronary I/R injury in vivo.
Validations of experimental model and methodology.
On the basis of the previous reports (4, 12, 20) , we chose the adequate dose of hydroxyfasudil, acetylcholine, papaverine, and L-NMMA to examine the effects of the Rho-kinase inhibition, endothelium-dependent and -independent vasodilator responses, and inhibition of NO synthesis on coronary vascular responses before and after coronary I/R, respectively. The methodologic validity of the present study has been confirmed previously (15) . After 60 to 90 min of ischemia, ultrastructural damage of coronary endothelium was observed particularly in the subendocardium in the present study, a consistent finding to the previous study (21) . Hydroxyfasudil as a specific Rho-kinase inhibitor in the coronary microcirculation in vivo. Shimokawa et al. (11) have recently demonstrated that hydroxyfasudil is a specific Rho-kinase inhibitor that markedly inhibits coronary vasospastic responses in a porcine model; its inhibitory effect on Rho-kinase is 100 times greater than on protein kinase C and Rho-kinase activity was determined by the degree of ezrin-radixin-moesin phosphorylation (p-ERM/t-ERM). Rho-kinase activation in the ischemic LAD was completely inhibited by cotreatment with hydroxyfasudil. Expression of eNOS protein in the ischemic endocardium of LAD area was significantly decreased compared with the non-ischemic endocardium of LCX area, which was again improved by hydroxyfasudil. *p Ͻ 0.05, **p Ͻ 0.01.
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1,000 times greater on myosin light-chain kinase. Hydroxyfasudil has potent vasodilator effects on coronary arteries through inhibition of Rho-kinase-mediated phosphorylations of myosin light chains (11) . In the present study, intracoronary hydroxyfasudil caused coronary microvascular vasodilation in a dose-dependent manner in vivo, and its vasodilator effect was greater in arterioles than in small arteries (Fig. 2) . Hydroxyfasudil suppressed the serotonin-induced vasoconstriction of small arteries, whereas it enhanced the serotonin-induced vasodilation of arterioles in vivo (Fig. 3) . This finding is in accordance with the hypothesis that the calcium sensitization of vascular smooth-muscle cells mediated by Rho-kinase plays a key role in the molecular mechanisms of coronary hyperconstriction (12) . Furthermore, in the present study, intracoronary L-NMMA significantly attenuated serotonin-induced coronary vasodilator responses, which were improved by hydroxyfasudil, indicating an involvement of NO-mediated mechanism in the beneficial effects of the Rho-kinase inhibitor. Lamping et al. (22) demonstrated that coronary vascular response to serotonin is determined by a balance between 5-HT 1 receptor-mediated dilatation of coronary arterioles and 5-HT 2 receptor-mediated vasoconstriction of small coronary arteries. Inhibition of NO synthase enhances coronary vasoconstriction to serotonin in both-sized arteries. Our present results are in agreement with those of Lamping et al. The beneficial vasodilator effect of hydroxyfasudil on coronary vascular response to serotonin is mediated by its action on both vascular smooth muscle and the endothelium as shown in Figure 3 . Thus, it is possible that the beneficial effect of Rho-kinase blockade with hydroxyfasudil is mediated by its action on both vascular smooth muscle and the endothelium (22) . Serotonin released by aggregating platelets has been implicated for coronary vasospasm in the presence of damaged vascular endothelium (5, 23) .
Beneficial effects of a Rho-kinase inhibitor on coronary I/R injury. In the present study, hydroxyfasudil exerted beneficial effects on I/R-induced endothelial injury in the canine coronary microcirculation in vivo through the NOdependent mechanism (Figs. 4 and 5 ). This dose of hydroxyfasudil (100 g/kg) selectively inhibits Rho-kinase activity and effectively prevents serotonin-induced coronary hyperconstriction. Recent studies have demonstrated that cGMP-dependent protein kinase inhibits RhoA phosphorylation by inhibiting the membrane binding of RhoA, in which the NO-mediated mechanism may inhibit the RhoA/Rho-kinase pathway (24 -26) . It was previously demonstrated that statins attenuate I/R injury of the heart and the brain in rats and mice, demonstrating the Rhomediated and NO-dependent protective effect of statins (27, 28) . Hydroxyfasudil also inhibits the production of superoxide anions in neutrophils (29) and various chemoattractant-induced migration of those cells (14) in a canine model of cerebral ischemia. Furthermore, treatment with hydroxyfasudil in human saphenous vein endothelial cells reversed the hypoxia-induced decrease in eNOS activity as examined by the citrulline conversion assay and 4,5-diaminofluorescein diacetate fluorescence method (13) . In the present study, I/R increased Rho-kinase activity, and hydroxyfasudil significantly inhibited the Rho-kinase activation. These findings suggest that NO is involved in the protective effect of hydroxyfasudil with an increase in eNOS activity and a decrease in Rho-kinase activity during reperfusion injury.
In the present study, the vasodilator effects of hydroxyfasudil were significantly attenuated by L-NMMA (Figs. 3  and 4) . The eNOS expression was decreased in the ischemic area of the endocardium compared with that of the epicardium under control conditions, which was improved by hydroxyfasudil (Fig. 7) . We have previously demonstrated that endocardial arteriolar dilation during reactive hyperemia is more sensitive to L-NMMA than epicardial arte- Rho-Kinase and Reperfusion Injury riolar dilation (30) . These findings indicate that the perfusion of the endocardium is more dependent on NO than that of the epicardium and that endothelial damage after I/R in arterioles may be greater in the endocardium than in the epicardium.
In the present study, hydroxyfasudil exerted cardiovascular protective effects on coronary I/R injury, as did preconditioning (31, 32) . However, the mechanism by which hydroxyfasudil and preconditioning protect coronary I/R injury appears to be different. Endogenous NO does not alter the infarct size after I/R and is not involved in the protective mechanism of preconditioning in pigs or rabbits (33, 34) . It has been suggested that preconditioning preserves myocardial creatine phosphate and intracellular pH (35) . Furthermore, ischemic preconditioning increases adenosine production and activates protein kinase C, which also enhances adenosine production during I/R injury.
In the present study, hydroxyfasudil significantly reduced myocardial infarct size with increment of coronary collateral blood flow, at least in part, thorough the NO-mediated mechanism (Fig. 8) . Shimokawa et al. (11) demonstrated that hydroxyfasudil inhibits both MLC mono-and diphosphorylations. Satoh et al. (14) showed that hydroxyfasudil also protects the brain from ischemic injury through inhibition of superoxide production and neutrophil infiltration. Mohri et al. (36) demonstrated that fasudil suppresses coronary microvascular spasm in patients with microvascular angina. Wolfrum et al. (37) recently demonstrated that inhibiting Rho-kinase has cardioprotective effects to reduce infarct size by activating phosphatidylinositol 3-kinase/ protein kinase Akt/eNOS pathways. All these mechanisms may be involved in the beneficial effects of hydroxyfasudil on the I/R-induced myocardial injury.
Hydroxyfasudil increases blood supply to the ischemic region of the myocardium and prevents I/R-induced myocardial injury. Furthermore, it has been recently demonstrated that an estrogen receptor modulator, raloxifene, also reduces I/R-induced myocardial infarct size, whereas an inhibitor of NO synthesis (L-NAME) or a blocker of calcium-activated K ϩ channels (charybdotoxin) partly attenuates the effect of raloxifene (19) . These results suggest that cardioprotective effects of those inhibitors may be mediated in part by the compensatory effects of NO and endothelium-derived hyperpolarizing factor (20) . Several studies using NO synthase inhibitors (38, 39) or eNOSdeficient mice (40) demonstrated an increase in infarct size after I/R. The effect of NO synthesis inhibition on the infarct size might be species-and dose-dependent. Clinical implications and conclusions. The present study has demonstrated for the first time that hydroxyfasudil, a specific Rho-kinase inhibitor, has NO-dependent cardiovascular protective effects on coronary I/R injury in vivo. Rho-kinase inhibitor has also an antianginal effect in a canine model of angina (41) , patients with effort angina (42) , and those with vasospastic angina (43) . Moreover, it has been recently reported that hydroxyfasudil may be effective for the treatment of pulmonary hypertension (44) . Indeed, Rho-kinase inhibitors may be useful for the treatment of a wide range of cardiovascular diseases (10) . The present study suggests that Rho-kinase inhibitors may also be useful for the treatment of coronary I/R injury in humans.
